NEW YORK (GenomeWeb) — Amoy Diagnostics has signed an agreement giving Sanomics the right to offer its multigene mutation detection kit in Hong Kong and Macau, the companies announced on Monday.
AmoyDx's kit is designed to detect 96 hotspot mutations/fusions in the EGFR, KRAS, BRAF, NRAS, HER2, PIK3CA, ALK, ROS1, and RET genes in tumor tissue to help guide treatment decisions for non-small cell lung cancer patients. It uses the firm's PCR-based ADx Amplification Refractory Mutation System technology and was approved by China's National Medical Products Administration in August.
According to the companies, Hong Kong-based Sanomics will offer the kit through its OncoSnap Nonet service. Additional terms of the deal were not disclosed.
About a year ago, Xiamen, China-based AmoyDx signed on Medikonia to distribute its molecular diagnostic tests in Hong Kong and Macau.